{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:15:51Z","timestamp":1783613751680,"version":"3.55.0"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["8720210101031CO"],"award-info":[{"award-number":["8720210101031CO"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009559","name":"Universidad Nacional de Quilmes","doi-asserted-by":"publisher","award":["1996\/18"],"award-info":[{"award-number":["1996\/18"]}],"id":[{"id":"10.13039\/501100009559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteosarcoma (OSA) is the most common primary malignant bone tumor and is characterized by high mortality, early metastatic dissemination, and extensive vascularization. Although overexpression of Vascular Endothelial Growth Factor A (VEGF-A) is associated with poor prognosis, clinical responses to the anti-VEGF-A monoclonal antibody Bevacizumab (BEVA) have been limited. Desmopressin (dDAVP), a hemostatic agent that acts as a selective arginine vasopressin receptor 2 (AVPR2) agonist, has demonstrated antitumor and angiostatic properties in other malignancies, however, its role in OSA remains incompletely characterized. This study evaluated the therapeutic potential of dDAVP as a coadjuvant strategy to enhance BEVA efficacy in OSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Bioinformatic analyses of AVPR2 expression and its associations with tumor aggressiveness, immune and stromal infiltration markers, and clinical outcomes were performed using TCGA-SARC and TARGET-OS datasets. Endothelial proliferation, migration, and morphogenesis were assessed in HmVEC-L and HMEC-1 microvascular cells. Antitumor activity was evaluated in human (MG-63) and murine (K7M3) OSA models.\n                      <jats:italic>In vivo<\/jats:italic>\n                      activity was assessed using xenogeneic and syngeneic models of tumor growth, metastasis, and tumor-associated angiogenesis. Combined dDAVP + BEVA therapy was evaluated\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      . Histopathological endpoints included mitotic index, desmoplasia, vimentin expression, and tumor necrosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Exploratory transcriptomic analyses revealed that AVPR2 expression was inversely associated with proangiogenic, prosurvival, and prometastatic gene signatures, while positively correlating with immune and stromal infiltration markers. Elevated AVPR2 expression was also associated with improved survival in both the pan-sarcoma cohort and a pediatric OSA subset. dDAVP significantly reduced pulmonary metastasis and OSA-driven vascularization\n                      <jats:italic>in vivo<\/jats:italic>\n                      and inhibited endothelial proliferation, migration, and morphogenesis\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Under tumor-conditioned conditions, dDAVP enhanced the antivascular activity of BEVA. Combined treatment with clinically relevant doses of dDAVP and BEVA significantly inhibited OSA xenograft progression without overt toxicity and favorably modulated histopathological markers of tumor aggressiveness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings support further translational evaluation of dDAVP as a potential adjuvant therapy in OSA, particularly in combination with BEVA. By targeting complementary angiogenesis-related mechanisms, this dual antiangiogenic strategy may improve therapeutic efficacy in OSA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1864843","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:21:16Z","timestamp":1782915676000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Luisina Mar\u00eda","family":"Solern\u00f3","sequence":"first","affiliation":[{"name":"Centro de Oncolog\u00eda Molecular y Traslacional (COMTra), Departamento de Ciencia y Tecnolog\u00eda, Universidad Nacional de Quilmes","place":["Buenos Aires, Argentina"]},{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer (IBioCan), Centro de Medicina Traslacional","place":["Hospital de Alta Complejidad en Red El Cruce \u201cDr. N\u00e9stor Kirchner, \u201d Buenos Aires, Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Llavona","sequence":"additional","affiliation":[{"name":"Centro de Oncolog\u00eda Molecular y Traslacional (COMTra), Departamento de Ciencia y Tecnolog\u00eda, Universidad Nacional de Quilmes","place":["Buenos Aires, Argentina"]},{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer (IBioCan), Centro de Medicina Traslacional","place":["Hospital de Alta Complejidad en Red El Cruce \u201cDr. N\u00e9stor Kirchner, \u201d Buenos Aires, Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahira Yasmine","family":"Saud","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer (IBioCan), Centro de Medicina Traslacional","place":["Hospital de Alta Complejidad en Red El Cruce \u201cDr. N\u00e9stor Kirchner, \u201d Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Carolina","family":"Onassis","sequence":"additional","affiliation":[{"name":"Hospital Interzonal de Ni\u00f1os \u201cEva Per\u00f3n,\u201d Catamarca","place":["Argentina"]},{"name":"Hospital de la Madre y el Ni\u00f1o","place":["La Rioja, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Florencia","family":"Gottardo","sequence":"additional","affiliation":[{"name":"Centro de Oncolog\u00eda Molecular y Traslacional (COMTra), Departamento de Ciencia y Tecnolog\u00eda, Universidad Nacional de Quilmes","place":["Buenos Aires, Argentina"]},{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer (IBioCan), Centro de Medicina Traslacional","place":["Hospital de Alta Complejidad en Red El Cruce \u201cDr. N\u00e9stor Kirchner, \u201d Buenos Aires, Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn Manuel","family":"Ledesma","sequence":"additional","affiliation":[{"name":"Hospital de Alta Complejidad en Red El Cruce \u201cDr. N\u00e9stor Kirchner","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Fernando","family":"Alonso","sequence":"additional","affiliation":[{"name":"Centro de Oncolog\u00eda Molecular y Traslacional (COMTra), Departamento de Ciencia y Tecnolog\u00eda, Universidad Nacional de Quilmes","place":["Buenos Aires, Argentina"]},{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer (IBioCan), Centro de Medicina Traslacional","place":["Hospital de Alta Complejidad en Red El Cruce \u201cDr. N\u00e9stor Kirchner, \u201d Buenos Aires, Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garona","sequence":"additional","affiliation":[{"name":"Centro de Oncolog\u00eda Molecular y Traslacional (COMTra), Departamento de Ciencia y Tecnolog\u00eda, Universidad Nacional de Quilmes","place":["Buenos Aires, Argentina"]},{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer (IBioCan), Centro de Medicina Traslacional","place":["Hospital de Alta Complejidad en Red El Cruce \u201cDr. N\u00e9stor Kirchner, \u201d Buenos Aires, Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ijc.24320","article-title":"International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.","volume":"125","author":"Mirabello","year":"2009","journal-title":"Int J Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/07357907.2020.1768401","article-title":"Epidemiology and risk factors of osteosarcoma.","volume":"38","author":"Sadykova","year":"2020","journal-title":"Cancer Invest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40744-016-0046-y","article-title":"Review of osteosarcoma and current management.","volume":"3","author":"Durfee","year":"2016","journal-title":"Rheumatol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1586\/14737140.2016.1168697","article-title":"Metastatic osteosarcoma: a challenging multidisciplinary treatment.","volume":"16","author":"Meazza","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10238-015-0382-1","article-title":"Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.","volume":"16","author":"Han","year":"2016","journal-title":"Clin Exp Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e13629","DOI":"10.1111\/ecc.13629","article-title":"Correlation of vascular endothelial growth factor with survival and pathological characteristics of patients with osteosarcoma: a systematic review and meta-analysis.","volume":"31","author":"Xin","year":"2022","journal-title":"Eur J Cancer Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e13102","DOI":"10.1111\/cpr.13102","article-title":"Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"B8","doi-asserted-by":"publisher","first-page":"864790","DOI":"10.3389\/fonc.2022.864790","article-title":"Bevacizumab, with sorafenib and cyclophosphamide provides clinical benefit for recurrent or refractory osseous sarcomas in children and young adults.","volume":"12","author":"Bodea","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/bjc.2015.351","article-title":"Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.","volume":"113","author":"Guo","year":"2015","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/ijc.30841","article-title":"A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.","volume":"141","author":"Navid","year":"2017","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/14740338.2023.2248876","article-title":"A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database.","volume":"23","author":"Tang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.16601","article-title":"Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database.","volume":"54","author":"Wichelmann","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology\u2013patient and health systems opportunities.","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations.","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.blre.2014.03.001","article-title":"Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding.","volume":"28","author":"Svensson","year":"2014","journal-title":"Blood Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e15087","DOI":"10.1200\/JCO.2024.42.16_suppl.e15087","article-title":"Repurposing hemostatic drug desmopressin in AVPR2-expressing triple-negative breast cancer: target expression analysis and preclinical antineoplastic effects on tumor growth and metastatic progression.","volume":"42","author":"Garona","year":"2024","journal-title":"J Clin Oncol."},{"key":"B17","first-page":"4761","article-title":"Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB\/c mice.","volume":"34","author":"Garona","year":"2014","journal-title":"Anticancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.4143\/crt.2018.040","article-title":"Preclinical Efficacy of [V4 Q5]dDAVP, a second generation vasopressin analog, on metastatic spread and tumor-associated angiogenesis in colorectal cancer.","volume":"51","author":"Garona","year":"2019","journal-title":"Cancer Res Treat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fonc.2017.00011","article-title":"Peptide agonists of vasopressin V2 receptor reduce expression of neuroendocrine markers and tumor growth in human lung and prostate tumor cells.","volume":"7","author":"Pifano","year":"2017","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3892\/etm.2021.9998","article-title":"Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma.","volume":"21","author":"Sobol","year":"2021","journal-title":"Exp Ther Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-07-0313","article-title":"Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.","volume":"13","author":"Gordon","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.3390\/ani13152507","article-title":"In silico and in vitro evaluation of bevacizumab biosimilar MB02 as an antitumor agent in canine mammary carcinoma.","volume":"13","author":"Cardama","year":"2023","journal-title":"Animals"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.3892\/ijo.2015.2952","article-title":"The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.","volume":"46","author":"Garona","year":"2015","journal-title":"Int J Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1608375","DOI":"10.3389\/fimmu.2025.1608375","article-title":"STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis.","volume":"16","author":"Shrestha","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15058","DOI":"10.1038\/s41598-022-18324-3","article-title":"Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy.","volume":"12","author":"Solern\u00f3","year":"2022","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human.","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1002\/ijc.28933","article-title":"Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.","volume":"135","author":"Fleuren","year":"2014","journal-title":"Int J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1245\/s10434-007-9779-8","article-title":"Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.","volume":"15","author":"Kim","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/vde.12726","article-title":"Intratumoral collagen index predicts mortality and survival in canine cutaneous mast cell tumours.","volume":"30","author":"Daniel","year":"2019","journal-title":"Vet Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12881-018-0722-6","article-title":"Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets.","volume":"19","author":"Kim","year":"2018","journal-title":"BMC Med Genet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"780264","DOI":"10.3389\/fonc.2021.780264","article-title":"Osteosarcoma and metastasis.","volume":"11","author":"Sheng","year":"2021","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"112391","DOI":"10.1016\/j.cellsig.2026.112391","article-title":"Tumour endothelial cells in cancer: chemo-physical crosstalk and angiogenic signalling in the tumour microenvironment.","volume":"141","author":"Ansardamavandi","year":"2026","journal-title":"Cell Signal"},{"key":"B34","doi-asserted-by":"publisher","first-page":"12067","DOI":"10.2147\/CMAR.S273466","article-title":"Extracellular collagen mediates osteosarcoma progression through an integrin \u03b12\u03b21\/JAK\/STAT3 signaling pathway.","volume":"12","author":"Wei","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e2409147","DOI":"10.1002\/advs.202409147","article-title":"Intratumoral collagen deposition supports angiogenesis suggesting anti-angiogenic therapy in armored and cold tumors.","volume":"12","author":"Mei","year":"2025","journal-title":"Adv Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"699212","DOI":"10.3389\/fcell.2021.699212","article-title":"A novel six metastasis-related prognostic gene signature for patients with osteosarcoma.","volume":"9","author":"Zheng","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"100357","DOI":"10.1016\/j.jbo.2021.100357","article-title":"Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices.","volume":"28","author":"Fasanya","year":"2021","journal-title":"J Bone Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.5858\/arpa.2015-0389-OA","article-title":"Histopathologic features of prognostic significance in high-grade osteosarcoma.","volume":"140","author":"Chui","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0210706","DOI":"10.1371\/journal.pone.0210706","article-title":"Viable and necrotic tumor assessment from whole slide images of osteosarcoma using machine-learning and deep-learning models.","volume":"14","author":"Arunachalam","year":"2019","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.52312\/jdrs.2023.902","article-title":"Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.","volume":"34","author":"Erdo\u011fan","year":"2023","journal-title":"Jt Dis Relat Surg."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e70224","DOI":"10.1002\/ddr.70224","article-title":"Desmopressin induces mitochondrial fragmentation and dysfunction in human U87 MG glioma cells via CaMKII-Drp1 signaling pathway.","volume":"87","author":"Liang","year":"2026","journal-title":"Drug Dev. Res"},{"key":"B42","first-page":"5049","article-title":"Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer.","volume":"30","author":"Ripoll","year":"2010","journal-title":"Anticancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.bbrc.2015.07.050","article-title":"A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.","volume":"464","author":"Sasaki","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B44","first-page":"295","article-title":"Angiostatic activity of 1-Deamino-8-D-Arginine vasopressin and novel peptide analogues in breast cancer cells.","volume":"68","author":"Ripoll","year":"2008","journal-title":"Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4103\/ijc.IJC_907_20","article-title":"Bevacizumab-containing regimens for children with relapsed or refractory tumors.","volume":"61","author":"Ya\u011fc\u0131-K\u00fcpeli","year":"2024","journal-title":"Indian J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.M109.030312","article-title":"Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.","volume":"284","author":"Baud\u2019huin","year":"2009","journal-title":"J Biol Chem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2010-01-264507","article-title":"Endothelial von Willebrand factor regulates angiogenesis.","volume":"117","author":"Starke","year":"2011","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.jtha.2023.03.027","article-title":"von Willebrand factor binds to angiopoietin-2 within endothelial cells and after release from Weibel-Palade bodies.","volume":"21","author":"Mobayen","year":"2023","journal-title":"J Thromb Haemost"},{"key":"B49","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11060-018-2820-x","article-title":"A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.","volume":"138","author":"Pace","year":"2018","journal-title":"J Neurooncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1395129","DOI":"10.3389\/fonc.2025.1395129","article-title":"Case report: bevacizumab-induced cerebrovascular events: a case series report and literature review.","volume":"15","author":"Chen","year":"2025","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.3390\/jcm11216254","article-title":"Metronomic chemotherapy in pediatric oncology: from preclinical evidence to clinical studies.","volume":"11","author":"Banchi","year":"2022","journal-title":"J Clin Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00244","article-title":"Metronomic chemotherapy for children in low- and middle-income countries: survey of current practices and opinions of pediatric oncologists.","volume":"5","author":"Revon-Rivi\u00e8re","year":"2019","journal-title":"J Glob Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10456-018-9613-x","article-title":"Consensus guidelines for the use and interpretation of angiogenesis assays.","volume":"21","author":"Nowak-Sliwinska","year":"2018","journal-title":"Angiogenesis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s40064-015-1217-y","article-title":"A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.","volume":"4","author":"Weinberg","year":"2015","journal-title":"Springerplus"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1038\/s41390-024-03642-1","article-title":"Desmopressin dosing in children using real-world data and pharmacokinetic\/pharmacodynamic model simulations.","volume":"97","author":"Yen","year":"2025","journal-title":"Pediatr Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/s0022-3476(89)80886-8","article-title":"Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions.","volume":"114","author":"Harris","year":"1989","journal-title":"J Pediatr"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/cancers15041221","article-title":"Endogenous extracellular matrix regulates the response of osteosarcoma 3D spheroids to doxorubicin.","volume":"15","author":"Cortini","year":"2023","journal-title":"Cancers"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41417-025-00970-0","article-title":"Unveiling the role of the extracellular matrix in the osteosarcoma tumor microenvironment through integrated transcriptomics and experimental validation.","volume":"32","author":"Liu","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.3390\/cancers15205108","article-title":"Decoding the impact of tumor microenvironment in osteosarcoma progression and metastasis.","volume":"15","author":"Nirala","year":"2023","journal-title":"Cancers"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/cells10071668","article-title":"The immune landscape of osteosarcoma: implications for prognosis and treatment response.","volume":"10","author":"Cascini","year":"2021","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","first-page":"82473","DOI":"10.18632\/oncotarget.12666","article-title":"Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials.","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1158\/1078-0432.CCR-13-2364","article-title":"Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.","volume":"20","author":"Turner","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J Thromb Haemost"},{"key":"B64","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/jnci\/djs232","article-title":"Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.","volume":"104","author":"Mochizuki","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"B65","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1538-7836.2005.01770.x","article-title":"Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice.","volume":"4","author":"Terraube","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5326\/JAAHA-MS-5509","article-title":"Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade.","volume":"47","author":"Hermo","year":"2011","journal-title":"J Am Anim Hosp Assoc"},{"key":"B67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jso.10141","article-title":"Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation.","volume":"81","author":"Giron","year":"2002","journal-title":"J Surg Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s10637-020-00914-5","article-title":"Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I\/II trial.","volume":"38","author":"Iseas","year":"2020","journal-title":"Invest New Drugs"},{"key":"B69","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrclinonc.2017.194","article-title":"Perioperative events influence cancer recurrence risk after surgery.","volume":"15","author":"Hiller","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis.","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/metabo15030178","article-title":"Antagonizing the S1P-S1P3 axis as a promising anti-angiogenic strategy.","volume":"15","author":"Avnet","year":"2025","journal-title":"Metabolites"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1013359","DOI":"10.3389\/fonc.2023.1013359","article-title":"Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.","volume":"13","author":"Fleuren","year":"2023","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3390\/v13102084","article-title":"Effect of ivermectin and atorvastatin on nuclear localization of importin alpha and drug target expression profiling in host cells from nasopharyngeal swabs of SARS-CoV-2- positive patients.","volume":"13","author":"Segatori","year":"2021","journal-title":"Viruses"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1864843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:46:13Z","timestamp":1783611973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1864843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":73,"alternative-id":["10.3389\/fmed.2026.1864843"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1864843","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1864843"}}